Sanofi (NASDAQ:SNY) Shares Sold by Y.D. More Investments Ltd

Y.D. More Investments Ltd reduced its stake in shares of Sanofi (NASDAQ:SNY) by 95.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,710 shares of the company’s stock after selling 258,630 shares during the period. Y.D. More Investments Ltd’s holdings in Sanofi were worth $632,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of SNY. Rise Advisors LLC grew its holdings in shares of Sanofi by 98.4% during the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after buying an additional 251 shares in the last quarter. Salem Investment Counselors Inc. acquired a new stake in shares of Sanofi during the fourth quarter worth $27,000. Venturi Wealth Management LLC increased its stake in Sanofi by 163.5% in the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock valued at $27,000 after purchasing an additional 332 shares during the last quarter. CNB Bank purchased a new position in Sanofi during the third quarter worth about $39,000. Finally, Farmers & Merchants Trust Co of Chambersburg PA boosted its stake in Sanofi by 115.6% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock worth $37,000 after buying an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Stock Performance

Sanofi stock traded up $0.80 during mid-day trading on Wednesday, reaching $50.03. The company’s stock had a trading volume of 1,340,383 shares, compared to its average volume of 2,016,453. The firm has a market cap of $126.56 billion, a price-to-earnings ratio of 24.71, a PEG ratio of 1.37 and a beta of 0.61. The business has a 50 day moving average price of $47.82 and a 200-day moving average price of $48.25. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. Sanofi has a twelve month low of $42.63 and a twelve month high of $55.93.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The business had revenue of $11.76 billion during the quarter, compared to analyst estimates of $13.02 billion. Sanofi had a return on equity of 19.69% and a net margin of 10.52%. Sell-side analysts predict that Sanofi will post 4.11 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be issued a $1.478 dividend. This represents a yield of 2.98%. The ex-dividend date is Thursday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.38. Sanofi’s payout ratio is currently 73.87%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on SNY shares. TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Finally, Morgan Stanley began coverage on shares of Sanofi in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target on the stock. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Sanofi currently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.